Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

Abstract: A system and method for engineering loss in a physical system by steering parameters of the physical system to the vicinity of an exceptional point is disclosed. In the vicinity of an exceptional point, localization of the fields helps to enhance any linear or nonlinear processes. As examples loss-induced transparency in the intracavity field intensities of coupled resonators, loss-induced suppression and enhancement of thermal nonlinearity in coupled resonators and loss-induced suppression and revival of Raman lasing in whispering-gallery-microcavities are demonstrated.

Abstract: Described is a composition that includes: (i) a drug against tuberculosis inhibiting the cytochrome b subunit of the bc1 complex, said cytochrome b subunit being encoded by the gene qcrB, in Mycobacterium tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable salt thereof.

Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions to treat or prevent an endoplasmic reticulum (ER) stress-mediated kidney disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an ER calcium channel stabilizing agent or an ER stress modulating agent (e.g., mesencephalic astrocyte-derived neurotrophic factor (MANF), compound K201).

Abstract: Disclosed herein is a transplantation graft for transplanting cells into a patient. In an aspect, the graft may include a first graft layer having a generally cylindrical configuration defining a lumen therethrough, a coating layer surrounding the first graft layer, and a plurality of cells or vectors implanted in either the first graft layer or the coating layer. Further disclosed herein is a method for transplanting cells into a patient and a method of treating a patient in need thereof. The transplantation graft may be implanted in the patient in an arteriovenous configuration and the coating layer protects the implanted cells from the patient's immune system. The plurality of cells in the transplantation graft may release a biologically active agent in response to a biological factor in blood flowing through the lumen of the transplantation graft.

Abstract: A brain-computer interface (BCI) system for modifying a subject's neural state are described that includes a neural activity sensor and a peripheral stimulation device operatively coupled to a computing device. A method of modifying a neural state of a subject is provided that includes receiving a target neural state from a system operator; detecting baseline neural activity signals; transforming the baseline neural activity signals into a peripheral stimulation pattern using an artificial intelligence model; administering a peripheral stimulation to the subject; detecting modified neural activity signals; and iteratively modifying the peripheral stimulation pattern to achieve a target neural state.

Abstract: Among the various aspects of the present disclosure is the provision of methods and systems for segmenting images and expediting a contouring process for MRI-guided adaptive radiotherapy (MR-IGART) comprising applying a convolutional neural network (CNN), wherein the CNN accurately segments organs (e.g., the liver, kidneys, stomach, bowel, or duodenum) in 3D MR images.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: A self-capacitance based remote power delivery device includes a modulating power source electrically coupled to a grounded substrate, an energy harvesting device coupled to the grounded substrate, and the substrate. The modulating power source is configured to be capacitively coupled to a self-capacitive body. The energy harvesting device configured to be capacitively coupled to the self-capacitive body, and the substrate is configured to be capacitively coupled to a portion of the self-capacitive body in direct contact with the substrate.

Abstract: The present disclosure is directed to refreshable biosensors and methods for synthesizing and refreshing same. In some embodiments, the refreshable biosensor comprises a plasmonic nanoparticle and a biorecognition element, wherein the biorecognition element is encapsulated with at least one of an organosilica polymer layer or a metal organic framework (MOF).

Abstract: A method comprising a series of selective extraction techniques for the parallel production of biodiesel and isolation of several valuable co-products including an alkenone hydrocarbon mixture of the kerosene/jet fuel range (primarily C10-, C12-, and C17-hydrocarbons) and fucoxanthin, a high-valued carotenoid, from the marine alkenone-producing microalgae Isochrysis.

Abstract: A gas cleaning system includes an inlet receiving a gas, an outlet spaced apart from the inlet, a gas channel defined between the inlet and the outlet to direct the gas from the inlet to the outlet, a photoionizer disposed to emit radiation towards a portion of the gas channel, and a first electrode module. The first electrode module includes a first discharge electrode assembly that generates a corona discharge within the gas channel and a first collection electrode assembly that collects ionized particles from the gas in the gas channel.

Abstract: Among the various aspects of the present disclosure is the provision of a methods and compositions for modulating IncRNAs and methods of treatment based on IncRNA expression.

Abstract: The invention encompasses a method for amplifying at least two different nucleic acid sequences. In particular, the method encompasses a multiplexed nucleic acid patch polymerase chain reaction.

Abstract: Disclosed herein are surgical suture materials that facilitate the sustained delivery of releasable components. The suture materials are processed by the disclosed methods to create a layer of pores extending inward from the outer surface of the suture. Particularly, the surgical suture materials are swollen in a calcium-ion containing solution, then freeze-dried to create pores which can be filled with a releasable component for ultimate delivery to the tissue. In one particular embodiment, the suture has an outer sheath that defines a lumen. Elongated filaments extend through the lumen. This suture embodiment is processed by the disclosed methods to yield a surgical suture material with a porous outer sheath. The pores enable efficient loading of a releasable component into the lumen, facilitating sustained delivery of the releasable component from the suture.

Abstract: A computer-implemented method for correcting artifacts within CT images of a subject includes providing iteratively correcting a CT volumetric image with a high-contrast mask by overpainting the high-contrast mask within CT volumetric image set by evaluating a model function and updating the CT projections to reflect the overpainting using a gradient descent based on previous overpainted CT projections, back-projecting the corrected CT projections to produce a corrected volumetric image set, and comparing the corrected CT volumetric image set against a previous corrected CT volumetric image set until convergence. The original voxels overpainted by the high-contrast mask are re-inserted into the converged CT volumetric image to produce the final CT volumetric image set.

Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

Abstract: Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Abstract: A structure of aligned (e.g., radially and/or polygonally aligned) fibers, and systems and methods for producing and using the same. One or more structures provided may be created using an apparatus that includes one or more first electrodes that define an area and/or partially circumscribe an area. For example, a single first electrode may enclose the area, or a plurality of first electrode(s) may be positioned on at least a portion of the perimeter of the area. A second electrode is positioned within the area. Electrodes with rounded (e.g., convex) surfaces may be arranged in an array, and a fibrous structure created using such electrodes may include an array of wells at positions corresponding to the positions of the electrodes.

Abstract: Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads, each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed for delivering a three-stage atrial cardioversion therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities delivered via the near-field configuration of the electrodes.